STAT - Reporting from the frontiers of health and medicine

Biotech

Health Tech

First Opinion

By David Vivero

Health ‘Maisie’s Army’: How a grassroots group is mobilizing to help toddlers access a lifesaving drug
First Opinion FDA should use its existing program to qualify new tools for drug safety testing
Pharmalot A drug maker replaces an old treatment and boosts the price by 1,300%
Pharmalot Endo agrees to pay $10 million to settle landmark opioid case brought by Ohio counties
Biotech Top scientist categorically denies any wrongdoing in Novartis data manipulation scandal

Exclusive analysis of biotech, pharma, and the life sciences

Daily, market-moving coverage of biotech and pharma

Inside intelligence on the NIH, the FDA, and Congress

Profiles of the power players shaping the industry

Analysis of the latest scientific developments

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future
Drug maker pays $200,000 to settle charges of unfairly disclosing material info to analysts
Pharmalittle: Two drug makers may settle opioid case; FDA hands Sarepta a surprising setback

Special Report

First Opinion

By Dorothy Pomerantz

Exclusive

Special Report

Health Tech

Biotech

Adam's Take FDA’s Sarepta rejection is rooted in the past, and will weigh on its future
Biotech A writer shared her story about getting frightening genetic results online. The response was surprising
First Opinion Containing the Ebola outbreak means addressing its root causes: a weak health system and insecurity
Health ‘Maisie’s Army’: How a grassroots group is mobilizing to help toddlers access a lifesaving drug
Biotech Top scientist categorically denies any wrongdoing in Novartis data manipulation scandal